Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol

F H E Staal*, J Janssen, C L Brouwer, J A Langendijk, K Ng Wei Siang, E Schuit, I J de Jong, J F Verzijlbergen, R J Smeenk, S Aluwini

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
23 Downloads (Pure)


BACKGROUND: Salvage external beam radiotherapy (sEBRT) for patients with a biochemical recurrence (BCR) after radical prostatectomy provides a 5-year biochemical progression-free survival up to 60%. Multiple studies have shown that dose escalation to the primary prostate tumour improves treatment outcome. However, data is lacking on the role of dose escalation in the recurrent salvage setting. The main objective of the PERYTON-trial is to investigate whether treatment outcome of sEBRT for patients with a BCR after prostatectomy can be improved by increasing the biological effective radiation dose using hypofractionation. Moreover, patients will be staged using the PSMA PET/CT scan, which is superior to conventional imaging modalities in detecting oligometastases.

METHODS: The PERYTON-study is a prospective multicentre open phase III randomised controlled trial. We aim to include 538 participants (269 participants per treatment arm) with a BCR after prostatectomy, a PSA-value of < 1.0 ng/mL and a recent negative PSMA PET/CT scan. Participants will be randomised in a 1:1 ratio between the conventional fractionated treatment arm (35 × 2 Gy) and the experimental hypofractionated treatment arm (20 × 3 Gy). The primary endpoint is the 5-year progression-free survival after treatment. The secondary endpoints include toxicity, quality of life and disease specific survival.

DISCUSSION: Firstly, the high rate of BCR after sEBRT may be due to the presence of oligometastases, for which local sEBRT is inappropriate. With the use of the PSMA PET/CT before sEBRT, patients with oligometastases will be excluded from intensive local treatment to avoid unnecessary toxicity. Secondly, the currently applied radiation dose for sEBRT may be too low to achieve adequate local control, which may offer opportunity to enhance treatment outcome of sEBRT by increasing the biologically effective radiotherapy dose to the prostate bed.

TRIAL REGISTRATION: This study is registered at (Identifier: NCT04642027 ). Registered on 24 November 2020 - Retrospectively registered. The study protocol was approved by the accredited Medical Ethical Committee (METc) of all participating hospitals (date METc review: 23-06-2020, METc registration number: 202000239). Written informed consent will be obtained from all participants.

Original languageEnglish
Article number416
Number of pages9
JournalBMC Cancer
Publication statusPublished - 15-Apr-2022


  • Clinical Trials, Phase III as Topic
  • Gallium Isotopes
  • Gallium Radioisotopes
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Neoplasm Recurrence, Local/diagnostic imaging
  • Positron Emission Tomography Computed Tomography/methods
  • Prospective Studies
  • Prostate/pathology
  • Prostate-Specific Antigen
  • Prostatectomy/methods
  • Prostatic Neoplasms/diagnostic imaging
  • Quality of Life
  • Radiation Dose Hypofractionation
  • Randomized Controlled Trials as Topic
  • Salvage Therapy/methods

Cite this